Identification and Treatment of Tuberculosis in Pediatric Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: Case Series and Review of the Literature
- PMID: 32801802
- PMCID: PMC7406069
- DOI: 10.2147/IDR.S256298
Identification and Treatment of Tuberculosis in Pediatric Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: Case Series and Review of the Literature
Abstract
Background: Tuberculosis is a rare but life-threatening complication in patients who received hematopoietic stem cell transplantation. Early identification and intervention are essential to prevent severe complications.
Case presentation: We report two pediatric patients who developed tuberculosis after receiving hematopoietic stem cell transplantation for thalassemia major among 330 recipients between January 2012 and August 2019. Patient A presented with pulmonary tuberculosis and patient B presented with lymph node tuberculosis mimicking post-transplantation lymphoproliferative disorder associated with Epstein-Barr virus reactivation. Patient B's condition was deteriorated, and shortly after the initiation of anti-tuberculosis therapy, the patient was found to have disseminated pulmonary tuberculosis. Patient B was also found to have tuberculous granulomas, an uncommon manifestation of tuberculosis causing severe airway obstruction. Both patients developed critical respiratory failure and required mechanical ventilation; however, they recovered with almost full resolution of pulmonary lesions after multiple treatment adjustments.
Conclusion: Tuberculosis must be carefully evaluated in all pediatric patients that receive hematopoietic stem cell transplantation, regardless of the identification of other pathogens. Prophylactic tuberculosis therapy should be considered for high-risk pediatric hematopoietic stem cell transplantation recipients from tuberculosis-endemic regions.
Keywords: hematopoietic stem cell transplantation; pediatric; thalassemia; tuberculosis.
© 2020 Wang et al.
Conflict of interest statement
The authors have no conflicts of interest to declare.
Figures

Similar articles
-
Rare tuberculosis in recipients of allogeneic hematopoietic stem cell transplantation successfully treated with contezolid-a typical case report and literature review.Front Cell Infect Microbiol. 2023 Oct 16;13:1258561. doi: 10.3389/fcimb.2023.1258561. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37908760 Free PMC article. Review.
-
Infections Caused by Mycobacterium tuberculosis in Recipients of Hematopoietic Stem Cell Transplantation.Front Oncol. 2014 Aug 26;4:231. doi: 10.3389/fonc.2014.00231. eCollection 2014. Front Oncol. 2014. PMID: 25207262 Free PMC article. Review.
-
Synchronous tuberculosis, Epstein-Barr virus-associated lymphoproliferative disorder and cytomegalovirus infection in an allogeneic transplant recipient: a case report.Springerplus. 2014 Jun 2;3:278. doi: 10.1186/2193-1801-3-278. eCollection 2014. Springerplus. 2014. PMID: 25019038 Free PMC article.
-
Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.Transplant Cell Ther. 2023 Feb;29(2):132.e1-132.e5. doi: 10.1016/j.jtct.2022.10.023. Epub 2022 Nov 9. Transplant Cell Ther. 2023. PMID: 36334653
-
Neuroimaging features of primary central nervous system post-transplantation lymphoproliferative disorder following hematopoietic stem cell transplant in patients with β-thalassemia: a case series and review of literature.Insights Imaging. 2024 Feb 14;15(1):40. doi: 10.1186/s13244-024-01605-y. Insights Imaging. 2024. PMID: 38353902 Free PMC article.
Cited by
-
Rare tuberculosis in recipients of allogeneic hematopoietic stem cell transplantation successfully treated with contezolid-a typical case report and literature review.Front Cell Infect Microbiol. 2023 Oct 16;13:1258561. doi: 10.3389/fcimb.2023.1258561. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37908760 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources